Disease severity, quality of life and health care in plaque-type psoriasis:: A multicenter cross-sectional study in Germany

被引:203
作者
Augustin, M. [1 ]
Krueger, K.
Radtke, M. A. [1 ]
Schwippl, I. [3 ]
Reich, K. [2 ]
机构
[1] Univ Clin Hamburg, Dept Dermatol, Hlth Econ & Qual Life Res Grp, DE-20246 Hamburg, Germany
[2] Dermatologikum Hamburg, Hamburg, Germany
[3] Essex Pharma GmbH, Munich, Germany
关键词
dermatology life quality index; plaque-type psoriasis; psoriasis area and severity index; quality of life;
D O I
10.1159/000119415
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Plaque-type psoriasis produces significant morbidity, has negative effects on patients' health-related quality of life (HRQoL), and represents an economic burden. Objectives: The assessment of disease severity, HRQoL and health care in plaque-type psoriasis in everyday German medical practice. Methods: Details of patients with plaque-type psoriasis were recorded by 48 dermatologists in Germany. During the visit, demographic data, medical history, previous and current treatments, occupational impairment, the current state of the disease (measured by the Psoriasis Area and Severity Index; PASI), overall lesion severity, and HRQoL were evaluated. Results: In total, 1,511 plaque-type psoriasis patients were included. The average PASI score was 12.0. The average Dermatology Life Quality Index score was 8.6. Among the patients with the severest psoriasis (PASI > 20), only 45.4% had ever been prescribed systemic treatments. Conclusions: Psoriasis patients have a reduced HRQoL and are not sufficiently treated in practice. A more widespread use of systemic treatment and the definition of treatment goals are essential to improve the standard of care for psoriasis patients. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:366 / 372
页数:7
相关论文
共 42 条
[1]  
Augustin M, 1999, HAUTARZT, V50, P715, DOI 10.1007/s001050051056
[2]  
Augustin M, 2004, EUR J DERMATOL, V14, P107
[3]  
AUGUSTIN M, 2000, DERMATOL PSYCHOSOM, V1, P84
[4]  
Berger Karin, 2005, J Dtsch Dermatol Ges, V3, P511, DOI 10.1111/j.1610-0387.2005.05729.x
[5]   AAD consensus statement on psoriasis therapies [J].
Callen, JP ;
Krueger, GG ;
Lebwohl, M ;
McBurney, EI ;
Mease, P ;
Menter, A ;
Paller, AS ;
Pariser, DM ;
Weinblatt, M ;
Zimmerman, G .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (05) :897-899
[6]   Assessment of values, utilities and preferences in cancer patients [J].
deHaes, JCJM ;
Stiggelbout, AM .
CANCER TREATMENT REVIEWS, 1996, 22 :13-26
[7]   European patient perspectives on the impact of psoriasis:: the EUROPSO patient membership survey [J].
Dubertret, L. ;
Mrowietz, U. ;
Ranki, A. ;
van de Kerkhof, P. C. M. ;
Chimenti, S. ;
Lotti, T. ;
Schaefer, G. .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (04) :729-736
[8]   Involving the patient: Impact of inflammatory skin disease and patient-focused care [J].
Feldman, S ;
Behnam, SM ;
Behnam, SE ;
Koo, JYM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (01) :S78-S85
[9]   DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].
FINLAY, AY ;
KHAN, GK .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216
[10]   PSORIASIS - AN INDEX OF DISABILITY [J].
FINLAY, AY ;
KELLY, SE .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1987, 12 (01) :8-11